Plasma Proteome Profiling of Coronary Artery Disease Patients: Downregulation of TransthyretinâAn Important Event

• Published in: Mediators of inflammation Vol. 2020
• Main Authors: Monu, Kharb, Rupsi, Sharma, Ankita, Chaddar, Monu Kumar, Yadav, Rakesh, Agnihotri, Prachi, Kar, Anand
• Format: Journal Article
• Language: English
• Published: John Wiley & Sons, Inc 10.11.2020
• Subjects: Cardiac patients; Care and treatment; Coronary heart disease; Diagnosis; Enzyme-linked immunosorbent assay; Ethylenediaminetetraacetic acid; Medical research; Medicine, Experimental; Proteins; Transluminal angioplasty; Germany; India
• ISSN: 0962-9351
• DOI: 10.1155/2020/3429541

Coronary artery disease (CAD) is a prevalent chronic inflammatory cardiac disorder. An early diagnosis is likely to help in the prevention and proper management of this disease. As the study of proteomics provides the potential markers for detection of a disease, in the present investigation, attempt has been made to identify disease-associated differential proteins involved in CAD pathogenesis. For this study, a total of 200 selected CAD patients were considered, who were recruited for percutaneous coronary intervention (PCI) treatment. The proteomic analysis was performed using two-dimensional gel electrophoresis (2-DE) and MALDI-TOF MS/MS. Samples were also subjected to Western blot analysis, enzyme-linked immunosorbent assay (ELISA), peripheral blood mononuclear cells isolation immunofluorescence (IF) analysis, analytical screening by fluorescence-activated cell sorting (FACS), and in silico analysis. The representative data were shown as mean±SD of at least three experiments. A total of 19 proteins were identified. Among them, the most abundant five proteins (serotransferrin, talin-1, alpha-2HS glycoprotein, transthyretin (TTR), fibrinogen-α chain) were found to have altered level in CAD. Serotransferrin, talin-1, alpha-2HS glycoprotein, and transthyretin (TTR) were found to have lower level, whereas fibrinogen-α chain was found to have higher level in CAD plasma compared to healthy, confirmed by Western blot analysis. TTR, an important acute phase transport protein, was validated low level in 200 CAD patients who confirmed to undergo PCI treatment. Further, in silico and in vitro studies of TTR indicated a downexpression of CAD in plasma as compared to the plasma of healthy individuals. Lower level of plasma TTR was determined to be an important risk marker in the atherosclerotic-approved CAD patients. We suggest that the TTR lower level predicts disease severity and hence may serve as an important marker tool for CAD screening. However, further large-scale studies are required to determine the clinical significance of TTR.